Minnesota medtech titan Medtronic (NYSE:MDT) won Canadian regulatory approval for its Reveal LINQ insertable cardiac monitor, announcing immediate commercial launch in the country.

The tiny device (smaller than a AAA battery) allows physicians to continuously monitor patients’ heart rhythms, connecting wirelessly with a home transmitter that sends information to Medtronic’s CareLink remote monitoring portal. The device is indicated for at-risk patients and those with irregular heartbeats, unexplained fainting or unexplained stroke, Medtronic said.

Medtronic won U.S. and European clearances for the Reveal LINQ system earlier this year.

Medtronic pioneered the field of insertable cardiac monitoring by commercializing the 1st system, which was invented by Canadian professor Dr. George Klein. The original iteration of the device was about the size of a standard USB stick, resulting in a more noticeable bump under the skin during implantation and leaving a larger scar.

The new Reveal LINQ can be implanted via an incision of less than 1 cm and comes with a set of specific implantation tools to simplify the process.

"The new Reveal LINQ is the result of many years of ongoing development to reduce its size, while adding wireless telemetry, enhancing performance, and improving benefits for patients," Medtronic Canada president Neil Fraser said in prepared remarks. "This innovative technology provides significant benefits for patients who need cardiac monitoring, and we look forward to providing them with the most technologically advanced and minimally invasive approach possible."